In this retrospective series of 265 patients with ≤3 cm, node-negative NSCLC treated with definitive radiotherapy (SBRT or proton therapy), the consolidation-to-tumor ratio (CTR)!https://www.advancesradonc.org/article/S2452-1094(26)00129-6/fulltext outperformed conventional T stage for prognostication. Patients with any ground-glass component (CTR <1.0) had outstanding outcomes whereas pure-solid tumors had worse OS, PFS, and DM. | Nakamura, Adv Radiat Oncol 2026
